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equate to reimbursement and treatment uptake, as therapies must also convinc-
ingly demonstrate cost-effectiveness as well as justifying budget impact.
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OBJECTIVES: The world’s worst outbreak of Ebola occurred in 2014 with 21,296 
cases and 8,429 deaths reported in total. The first case of Ebola was recorded on 
30th September by Centers for Disease Control and Prevention (CDC) in the US. 
Pharmacists can play an important role in treating Ebola patients. The aim of this 
study is to assess knowledge and attitude about Ebola among U.S. pharmacy stu-
dents. METHODS: This was a cross sectional survey study. An Ebola questionnaire 
was distributed among third year pharmacy students in a private university in 
the U.S. before and after delivering an educational Ebola seminar based on the 
CDC and World Health Organization Ebola fact sheet N103. The questionnaire com-
prised of 33 questions was divided into three components: demographics (3), Ebola 
knowledge (25) and attitude about Ebola (5). Paired t test and McNemar test were 
employed using SPSS version 21. RESULTS: A total of 103 pharmacy students partici-
pated in the survey. The study population had a highly significant increase in Ebola 
related knowledge about species (p< 0.001), incubation period (p< 0.001), diagnosis 
(p< 0.001), vaccination (p< 0.05), treatment (p< 0.001), complications (p< 0.001) and 
immunity (p< 0.01). Also, a significant number of study participants had a positive 
attitude about treating Ebola patients and believed that Ebola patients should be 
kept isolated (p< 0.05) and communities should actively participate in preventing 
the spread of Ebola (p< 0.05). CONCLUSIONS: Students, upon becoming PharmD 
professionals can apply the knowledge acquired through this study for effectively 
treating patients. Focused seminars are a valuable tool to improve student aware-
ness of infectious disease.
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OBJECTIVES: Antibiotics in clinical practice in Slovakia are often indicated unneces-
sarily and without proper differential diagnosis that differentiate viral form bacte-
rial etiologic agents. Due to the frequent indications of antibiotics in praxis are 
consumption trends increasing, there is greater financial burden an the health 
care as well as we can observe unjustified consumption. In consequence the resist-
ance of microorganisms to antibiotics is increasing. METHODS: Our work aims 
to give an image of the current prescribing behaviour of physicians involved in 
the project SKANT – The School of Antibiotic Therapy. It evaluates trends in anti-
biotic prescription in the treatment of respiratory diseases, the etiology of infec-
tions, antibiotic administration merits focused on Slovakia during first quarter of 
2013. Implementation by validate questionnaire study of prescribing in general 
practitioners for adults and general practitioners for children and adolescents in 
Slovakia. RESULTS: According to the evaluated data there is high consumption 
in the group of penicillins and macrolides. The unjustified prescription of mac-
rolides 24.58% due to allergy of patients to penicillins 4.67%. In these respiratory 
diseases, antibiotics were most frequently indicated: Sinusitis acuta (79.47%), 
Tonsilopharyngitis acuta (69.78%), Bronchitis acuta and Tracheobronchitis acuta 
(68.80%) The use of microbiological and biochemical tests were observed in 26.5% 
of patients. In 73.5% not used any of these tests. CONCLUSIONS: Analysis of treat-
ment with antimicrobial drugs for acute respiratory diseases confirmed the current 
trend of increasing prescription in Slovakia. Excessive consumption of antibiotics 
often leads to unwanted spread of antimicrobial resistance and the ineffectiveness 
of existing drugs to fight infections. The solution unfavorable situation is repeated 
audits of prescribing antimicrobial drugs. Based on the results of our study we sug-
gest prepare educational training for laic and professional public.
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OBJECTIVES: Skin and soft tissue infections (SSTI) are among the most common 
hospital infections, and represent a heterogeneous range of infection types with 
numerous treatment options. While recent research has begun to characterize 
treatment patterns and associated outcomes, little is known about country-specific 
practice patterns. The purpose of this analysis was to characterize current prac-
tice patterns in the treatment of SSTIs in select European countries. METHODS: A 
retrospective analysis was conducted using Arlington Medical Resources’ (AMR’s) 
Hospital Antibiotic Market audit January-June 2013. The audit is comprised of data 
elements including patient demographics, diagnosis, therapy sequence, switching, 
and concomitance, hospital and intensive care unit, length of stay, discharge drug, 
and drug costs. RESULTS: A sample of adult inpatients with SSTIs projected to 
national volume in Germany (n= 427,516), United Kingdom (UK; n= 292,265), Italy 
(n= 199,588) and Spain (195,084) were included for analysis. Demographic charac-
teristics were similar across countries; diabetes and heart disease were the most 
common comorbidities. Practice patterns varied considerably; the most common 
first-line treatment was ampicillin/sulbactam (22.1%) in Germany, flucloxacillin 
(31.9%) in UK, ceftriaxone (10.7%) in Italy, and amoxicillin/clavulanate (21.2%) in 
Spain. MRSA rates across all SSTIs were 3.5%, 4.9%, 3.3%, and 3.4% in Germany, UK, 
pneumococcal vaccination coverage and factors associated with receiving pneu-
mococcal vaccination in U.S. adults with high-risk conditions encompassed by the 
ACIP recommendation. METHODS: This retrospective observational cohort study 
included commercially-insured adults aged 19-64 years with newly-diagnosed 
chronic medical conditions from 2007-2010. Outcomes of interest include pneu-
mococcal vaccination coverage and time from initial diagnosis to pneumococcal 
vaccination. RESULTS: Among 300,556 U.S. adults with high-risk conditions, 30% 
had their condition diagnosed by primary care physicians. On average, these adults 
visited pharmacy, doctor’s office, outpatient hospital, inpatient hospital and emer-
gency department 38.3, 27.3, 6.6, 0.4, and 1.4 times, respectively, during an average 
2.6 years of follow-up. Nevertheless, overall pneumococcal vaccination coverage was 
only 6.9%. Coverage was highest in patients with HIV (32.1%), followed by diabetes 
(11.2%), chronic lung disease (8.5%), asplenia (6.8%), chronic renal disease (5.9%), 
chronic heart disease (5.7%), cochlear implant (4.4%), cancer (4.2%), chronic liver 
disease (3.7%), alcoholism (2.5%), and transplant (2.0%). Among those who received 
pneumococcal vaccination, the majority was vaccinated in the physician’s office 
(99%); average time from initial diagnosis to vaccination was 469 days, ranging 
from 198 days for HIV to 576 days for chronic liver disease. Multivariable logistic 
regression showed that adults who were older, initially diagnosed by primary care 
physicians, received influenza vaccination, had more conditions or more healthcare 
encounters were more likely to receive pneumococcal vaccination. CONCLUSIONS: 
Pneumococcal vaccination coverage in adults with high-risk conditions was far 
below the Healthy People 2020 objective. Findings suggest missed opportunities 
continue and better interventions needed to improve pneumococcal vaccination 
during healthcare encounters for this vulnerable population.
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OBJECTIVES: Adults are increasingly receiving vaccinations outside of traditional 
doctor’s office setting. This study aimed to examine, from the patient’s perspective, 
drivers and behaviors of adult vaccinations across various settings. METHODS: 
A cross-sectional, self-administered, online survey was conducted in U.S. nation-
ally representative adults aged at least 19 years who received either influenza, 
pneumococcal, or zoster vaccine within the past 6 months. The survey explored 
attitudes, preferences, and behaviors of adults vaccinated at various settings. 
Descriptive and bivariate analyses were applied to analyze patients’ responses 
by each vaccine and setting. RESULTS: Among 1,178 qualified respondents, 46.0% 
were vaccinated at doctor’s office, 37.1% at pharmacy, and the remaining at other 
clinical or community settings. Other than doctor’s office or pharmacy, the most 
common alternative setting to receive vaccination was workplace for influenza 
vaccine (15.5%), and hospital/emergency room for pneumococcal (9.3%) and zoster 
(5.5%) vaccines. Adults were more likely to know about the vaccines offered at 
the doctor’s office directly from physicians (68.6%), while the majority of adults 
knew about vaccines offered at the pharmacy from seeing signs in the pharmacy 
(37.8%). Consistent across all three vaccines, the main drivers for selecting vac-
cination settings were “This location accepts my insurance”, followed by “This is 
a location I already visit for other reason” and “I was able to vaccinate without an 
appointment”. The primary reason for choosing to vaccinate at the doctor’s office 
was “This is a location I already visit for other reasons”, for pharmacy was “The 
location accepts my insurance”, and for other settings was “Lower out-of-pocket 
cost”. Among all respondents, 17.7% received two or more vaccines concurrently, 
with convenience and healthcare provider recommendation reported as the main 
drivers. CONCLUSIONS: Findings suggest opportunities to improve adult vacci-
nation at traditional and non-traditional settings, and highlight importance of 
healthcare provider recommendation in adult vaccination.
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OBJECTIVES: In 2011, the introduction of boceprevir and telaprevir was hailed as a 
breakthrough in the hepatitis C (HCV) treatment paradigm, but these treatments 
were not widely adopted due to cost and safety concerns. 4 years on, the intro-
duction of newer, more effective therapies (e.g. simeprevir and sofosbuvir) has re-
revolutionized the HCV space. However, cost concerns continue to limit the number 
of patients being treated with new medicines. To inform future submissions, HCV 
reimbursement decisions across 5 HTA agencies were assessed and the underlying 
rationale examined. METHODS: NICE, SMC, PBAC, CADTH, and TLV were searched 
for guidance on HCV medicines between December 2010 and December 2014. 
Recommendations for and rationale behind each decision were extracted. RESULTS: 
Boceprevir and telaprevir had each been assessed 6 times across the different agen-
cies including resubmissions: PBAC initially rejected both, then restricted both 
dependent on reduced price at resubmission; CADTH also restricted both depend-
ent on reduced price. Submissions were accepted in-line with the label by the other 
agencies. Reasons for rejection/restriction of boceprevir and telaprevir included 
cost-effectiveness concerns, uncertain efficacy in some patient populations, and 
safety concerns. Simeprevir had been assessed 4 times with 1 in development: 
CADTH and TLV restricted simeprevir due to uncertainty over cost-effectiveness 
and efficacy in some genotypes; PBAC and SMC accepted simeprevir. Sofosbuvir 
had been assessed 4 times with 1 in development: PBAC rejected sofosbuvir due to 
unacceptable cost-effectiveness and high budget impact; CADTH and TLV restricted 
sofosbuvir dependent on reduced price; SMC accepted sofosbuvir. CONCLUSIONS: 
Despite higher cure rates achieved with newer treatment options, cost-effectiveness 
concerns remain the primary reason for rejection or restriction of HCV therapies 
by HTA agencies. Manufacturers should not assume that high clinical efficacy will 
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II instrument in relation to 6 domains proposed. Literature review of diagnosis 
criteria and when to start antiretroviral therapy according to recommended 
guidelines in people living with HIV, following search criteria in the WHO docu-
ment. RESULTS: We established methodological deficiencies in domains 3, 5 
and 6 of AGREE II in the guideline quality assessment. On Domain 3 “Rigour of 
Development” , despite the systematic literature review and quality assessment 
of the evidence reported, recommendations are based on low and very low qual-
ity information, according to GRADE. It means that the recommendations could 
have a high level of uncertainty in the estimation of long term toxicity of first line 
regimes as well as when to start therapy. In Domain 5 “Applicability” we found a 
limitation since the local context on availability of resources, the cost of products 
and other restrictions were practically ignored. States should be obliged to conduct 
this analysis before local adoption with implications of transferability and perti-
nence. Last, in Domain 6 “Editorial Independence” we found the most worrisome 
issue. The 41% of Guideline Development Group members and 25% peer review-
ers disclaimed membership of pharmaceutical industry or other advisory pan-
els, have receipt consulting fees or declared financial support through grants for 
research. Nevertheless, WHO considered this conflict of interest not relevant which 
decrease transparency and credibility of recommendations. CONCLUSIONS: 
Guidelines from WHO constituted an important global reference, however the 
way that HIV guidelines were developed showed worrisome deficiencies in qual-
ity, transparency and transferability. Since the independence of WHO is a matter 
of global controversy, countries must conduct a revision before the adoption of 
guidelines.
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OBJECTIVES: To describe the occurrence rates and causality evidence of cancer 
medication–associated adverse drug reactions (ADRs) and to evaluate Medication 
Utilization in managing the occurred ADRs. METHODS: The patient’s data was 
collected using patient data collection forms in inpatient Radiotherapy depart-
ment. The ADR assessment is done by using WHO causality assessment scale and 
Naranjo’s causality assessment scale. RESULTS: In a total of 536 patients, 78% 
(n= 418) experienced adverse drug reactions. Patients with single adverse drug 
reaction are 43% (n= 178) of 418, whereas 23% (n= 96) experienced two adverse drug 
reactions and 9% (n= 38) were found to be experiencing more than 2 adverse drug 
reactions. Alopecia 95% (n= 397), Nausea and vomiting 82% (n= 343), myelosuppres-
sion 42.1% (n= 176), Skin pigmentation 15.3% (n= 64), itching 11.4% (n= 48), Diarrhea 
11% (n= 46), mucositis 10.2% (n= 43), Constipation 6.22% (n= 26), cardiotoxicity 2% 
(n= 8) are most commonly observed ADRs. The drugs and their proportions for man-
agement of chemotherapy induced adverse drug reactions include Filgrastim (100%), 
metachlopromide (87.0%), different antibiotics like Piperacillin+Tazobactum (77.8%), 
Ceftriaxone (73.3%), Ondansetron (70%) and Dulcolax (66.6%). CONCLUSIONS: 
Approximately 78% of patients taking chemotherapy experienced adverse drug 
reactions that are mostly managed by utilizing proper medications, which further 
elucidate the opportunity for clinical pharmacists to monitor and manage adverse 
drug reactions cautiously, thereby minimizing the after effects of chemotherapy 
and improving the patient’s outcomes.
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OBJECTIVES: Active Surveillance (AS) pharmacovigilance systems better estimate 
the burden of adverse events (AEs) and generate information to allow for more 
efficient use of medicines. The objective of this activity was to implement an AS 
pilot program for first-line antiretroviral therapy (ART) medicines at 2 sentinel sites 
in Namibia. METHODS: The sentinel sites were Windhoek Central Hospital and 
Katutura Intermediate Hospital. Adults naïve to ART were enrolled, an AS Data 
Collection Form was developed and placed into the patient chart, and the doctor 
recorded ART and health information including actively recorded the presence or 
absence of AEs during each follow-up visit. We evaluated data quality by comparing 
data collected through AS forms to medical charts. We assessed incidence of AEs 
using a Cox proportional hazard model. RESULTS: A total of 413 eligible patients 
were included from August 2012 to April 2013. Demographic variables were com-
pleted on average 30% of the time and follow-up visits recorded for 82% of patients. 
Average age was 37 years; WHO Clinical Stage I for 51%; mean baseline CD4 count 
216. Most common ART regimen was TDF/3TC/NVP. The incidence of experiencing 
at least one AE was 0.3/100 person-years. Most common AE was rash followed by 
abdominal pain. After adjustment for age, gender, WHO stage, and CD4 count, those 
on TDF/3TC/EFV had 17.6 times higher risk of experiencing at least one AE (p= 0.002, 
95% CI 2.8-111.8) compared to those on TDF/3TC/NVP, and those with WHO Stage 
2 had 8.8 times higher risk (p= 0.01, 95% CI 1.9-41.2) compared to those with WHO 
Stage 1 disease. CONCLUSIONS: ART regimen and WHO stage influence the risk 
of AEs in Namibia. The quality of data collected through active surveillance in a 
resource-limited setting was high. An economic evaluation is being undertaken to 
evaluate overall feasibility of scale-up of the AS system.
Italy, and Spain, respectively. Empiric treatment with MRSA-active agents was less 
common, with teicoplanin (7.8% in Italy), clindamycin (5.9% in Spain) and van-
comycin (5.8% in Spain) among the most commonly used agents. 38.5%, 71.0%, 
48.0%, and 52.3% of patients were discharged onto continued treatment in Germany, 
UK, Italy, and Spain, respectively. Treatment switching was frequent across coun-
tries. CONCLUSIONS: Treatment of SSTIs is heterogeneous across European coun-
tries; further research is needed to understand the association between empiric 
treatment, treatment switching, and patient outcomes. This analysis, however, 
highlights the potential need for reassessment of treatment guidelines for SSTI 
and the potential need for new SSTI treatments.
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OBJECTIVES: Once-daily STRs have become an increasingly popular choice for both 
newly initiating and treatment experienced patients to improve patient adherence 
and achieve optimal outcomes. This study examines how STR prescribing trends 
have evolved in key EU countries (France, Germany, Italy, Spain and the UK) and pro-
vides insight into physician motivation to switch from conventional anti-retroviral 
(ARVs) regimen dosing to STRs. METHODS: Multi-wave retrospective medical chart 
reviews of HIV patients have been conducted in big-5-EU since 2005 to study patients 
initiating or switching ARVs during each quarter (Q) of the year. Physicians were 
recruited from a large panel to be geographically representative; they abstracted 
patient demographic, disease, and treatment data for next few consecutive HIV 
patients they encountered within a defined time period. This analysis focuses on 
STR prescribing trends between 1Q2009 and 4Q2014. RESULTS: Over 200 physicians 
abstracted 3132 and 3045 patient charts in 1Q2009 and 4Q2014 respectively. STR use 
increased in EU from 17% (France:0.5%, Germany:12%, Italy:16%, Spain:29%, UK:29%) 
in 1Q2009 to 51% in 4Q2014 (France:50%, Germany:67%, Italy:41%, Spain:51%, 
UK:46%). The top reason for switching from conventional ARV dosing to an STR 
across big-5 EU in 1Q2009 was simplification (72%), followed by tolerability (14%), 
and patient decision (12%). Importance of tolerability (19%) increased over the past 
5 years in the decision to switch, while simplification (64%) decreased; patient deci-
sion increased slightly (18%). CONCLUSIONS: STR adoption in the big-5 EU countries 
studied increased rapidly, with Germany and France having the largest increases 
from 1Q2009 to 4Q2014. There was a marked change in impetus to switch to STRs 
from simplification alone to an increasing focus on tolerability. These observed 
trends may emphasize the importance HIV providers give towards maintaining HIV 
patients on a simple and yet tolerable regimen to achieve optimal adherence and 
clinical outcomes over the longer term.
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OBJECTIVES: Acute bacterial skin and skin structure infections (ABSSSI) are among 
the most common infections treated in the hospital setting, and analysis of hos-
pital claims indicate that approximately 74% of ABSSSI hospitalizations involve 
empiric treatment with methicillin-resistant Staphylococcus aureus(MRSA)-active 
antibiotics. Many patients continue treatment post-hospital discharge; little is 
known, however, about real-world prescribing patterns. The purpose of this 
analysis was to characterize current prescribing patterns at hospital discharge 
in the United States (US). METHODS: A retrospective analysis was conducted 
using Arlington Medical Resources’ (AMR’s) Hospital Antibiotic Market audit, 
January-June 2011. The audit is comprised of data elements including patient 
demographics, diagnosis, therapy sequence, switching, and concomitance, hos-
pital and intensive care unit (ICU) length of stay (LOS), discharge drug, and drug 
costs. RESULTS: A sample of 781,331 adult hospitalized patients with ABSSSI who 
received MRSA-active IV antibiotics, projected to national volume, were included 
for analysis. Vancomycin was the most commonly prescribed MRSA-active anti-
biotic, administered to 57.07% of patients at any time during hospitalization. 
Linezolid IV (3.84%), tigecycline (2.88%), and daptomycin (1.92%) were used less 
frequently. Approximately 31% of patients were discharged with an order for 
MRSA-active IV antibiotics. Vancomycin was the most commonly prescribed IV 
antibiotic at discharge, prescribed to 24.83% of patients. Daptomycin was the next 
most commonly prescribed IV drug at discharge (3.71%). All other IV antibiotics 
were prescribed in < 1% of patients. Many patients were prescribed oral antibiot-
ics at discharge, and may have been prescribed more than one drug. Cephalexin 
(33.99%), TMP-SMZ (17.22%), clindamycin (11.08%), and linezolid (9.45%) were the 
most commonly prescribed oral antibiotics at hospital discharge. CONCLUSIONS: 
Approximately 40% of ABSSSI patients are discharged on a MRSA-active antibiotic. 
MRSA-active antibiotics that do not require multiple days of ambulatory treat-
ment following hospitalization have the potential to reduce resource utilization 
associated with continued outpatient treatment.
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OBJECTIVES: To conduct an assessment of the quality of “Consolidated guide-
lines on the use of antiretroviral drugs for treating and preventing HIV infec-
tion. Recommendations for a public health approach June 2013” by World Health 
Organization (WHO). METHODS: Quality assessment of guideline using AGREE 
